Trial Profile
Short-term proof-of-principle trial of ripirivine (TMC278) in patients with HIV-1 infections who previously failed antiretroviral therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2010
Price :
$35
*
At a glance
- Drugs Rilpivirine (Primary) ; Nucleoside reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Proof of concept; Therapeutic Use
- 05 Nov 2010 New trial record.